WASHINGTON--(BUSINESS WIRE)--The Global Alzheimer's Platform Foundation® (GAP) and the Scottish Funding Council’s Brain Health ARC have announced swift progress in the next steps of the Bio-Hermes ...
Washington D.C., Jan. 23, 2025 (GLOBE NEWSWIRE) -- The Global Alzheimer’s Platform Foundation® (GAP) is pleased to welcome Beckman Coulter Diagnostics as a strategic partner in the Bio-Hermes-002 ...
The data for the challenge came from GAP’s Bio-Hermes study, which brought together the world’s leading digital and traditional cognitive assessment companies along with leading pharmaceutical ...
WASHINGTON, Jan. 12, 2026 (GLOBE NEWSWIRE) -- The Global Alzheimer’s Platform Foundation ® (GAP) is pleased to welcome Spear Bio, a biotechnology company pioneering wash-free ultrasensitive ...
NEW YORK CITY, NY, UNITED STATES, December 10, 2024 /EINPresswire.com/ -- ViewMind Inc., a leader in eye movement technology, announces its participation in the Bio ...
The Global Alzheimer's Platform Foundation ®, (GAP) is releasing the first results from the Bio-Hermes-001 Study. This study in over 1000 community-based participants from throughout the US compared ...
Washington D.C., Feb. 28, 2024- The Global Alzheimer’s Platform Foundation ®, (GAP) is releasing the first results from the Bio-Hermes-001 Study. This study in over 1000 community-based participants ...
WASHINGTON, Jan. 09, 2026 (GLOBE NEWSWIRE) -- The Global Alzheimer’s Platform Foundation ® (GAP) is pleased to welcome Alamar Biosciences, a company powering ...
Bio-Hermes biospecimens are routinely used for biomarker discovery, analytical validation, clinical utility, and clinical validation studies. The Bio-Hermes-001 study compared the results of blood and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results